{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:04:56Z","timestamp":1783573496974,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We conducted a retrospective review of multiple myeloma (MM), smoldering multiple myeloma (SMM), and monoclonal gammopathy of undetermined significance (MGUS) patients seen at Mayo Clinic to determine whether a bone marrow biopsy (BM) is necessary in all patients diagnosed with a monoclonal protein. A total of 2254 MM, 397 SMM, and 5836 MGUS patients were included in the study. A total of 29 (1.3%) MM patients \u201cwithout CRAB\/FLC\u201d were identified where BM or advanced imaging was critical for diagnosis, 8 (0.3% MM cohort) of whom were diagnosed with MM solely on BM findings (plasma cells\u2009&gt;\u200960%). Without BM or advanced imaging none of these patients would be classified low-risk MGUS. A total of 314 (79%) MGUS-like SMM patients were identified where classification of SMM was based on BM findings. Without BM 97 would be classified as low\/low-intermediate-risk MGUS and 151 intermediate or high-risk MGUS; 66 had missing information precluding classification. Only three (&lt;1% SMM cohort) were low-risk MGUS without abnormalities in hemoglobin, calcium, and renal function. In patients presenting with low-risk MGUS and normal hemoglobin, calcium, and renal function, the risk of missing a diagnosis of SMM and MM by omitting BM is &lt;1%. BM should be deferred in these patients in preference to clinical and laboratory monitoring.<\/jats:p>","DOI":"10.1038\/s41408-020-0319-0","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T12:03:53Z","timestamp":1588766633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?"],"prefix":"10.1038","volume":"10","author":[{"given":"M. Hasib","family":"Sidiqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Aljama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie L.","family":"Fonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam A.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Lisa","family":"Hwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"Vincent S.","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"319_CR1","unstructured":"National Cancer Institute. SEER Stat Fact Sheets: Myeloma (National Cancer Institute, 2018) http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"319_CR2","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412\u20135417 (2009).","journal-title":"Blood"},{"key":"319_CR3","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar, S. V., Landgren, O. & Mateos, M. V. Smoldering multiple myeloma. Blood 125, 3069\u20133075 (2015).","journal-title":"Blood"},{"key":"319_CR4","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","volume":"375","author":"A Dispenzieri","year":"2010","unstructured":"Dispenzieri, A. et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 375, 1721\u20131728 (2010).","journal-title":"Lancet"},{"key":"319_CR5","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"319_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 (2018).","journal-title":"Blood Cancer J."},{"key":"319_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/ejh.12728","volume":"97","author":"R Sorrig","year":"2016","unstructured":"Sorrig, R. et al. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. Eur. J. Haematol. 97, 303\u2013309 (2016).","journal-title":"Eur. J. Haematol."},{"key":"319_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","volume":"148","author":"E Perez-Persona","year":"2010","unstructured":"Perez-Persona, E. et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br. J. Haematol. 148, 110\u2013114 (2010).","journal-title":"Br. J. Haematol."},{"key":"319_CR9","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E Perez-Persona","year":"2007","unstructured":"Perez-Persona, E. et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110, 2586\u20132592 (2007).","journal-title":"Blood"},{"key":"319_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/ajh.10003","volume":"68","author":"SV Rajkumar","year":"2001","unstructured":"Rajkumar, S. V. et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am. J. Hematol. 68, 269\u2013275 (2001).","journal-title":"Am. J. Hematol."},{"key":"319_CR11","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R. et al. International Staging System for multiple myeloma. J. Clin. Oncol. 23, 3412\u20133420 (2005).","journal-title":"J. Clin. Oncol."},{"key":"319_CR12","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar, S. V. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106, 812\u2013817 (2005).","journal-title":"Blood"},{"key":"319_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","volume":"131","author":"RS Go","year":"2018","unstructured":"Go, R. S. & Rajkumar, S. V. How I manage monoclonal gammopathy of undetermined significance. Blood 131, 163\u2013173 (2018).","journal-title":"Blood"},{"key":"319_CR14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","volume":"17","author":"MV Mateos","year":"2016","unstructured":"Mateos, M. V. et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 17, 1127\u20131136 (2016).","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"319_CR15","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1200\/JCO.2019.37.15_suppl.8001","volume":"37","author":"S Lonial","year":"2019","unstructured":"Lonial, S. et al. E3A06: randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. J. Clin. Oncol. 37(15_suppl), 8001\u20138001 (2019).","journal-title":"J. Clin. Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0319-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:28:01Z","timestamp":1670250481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0319-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0319-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"3 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D. received research funding from Celgene, Millennium, Pfizer, and Janssen, and travel grant from Pfizer. M.A.G. received consultancy from Millenium and honoraria from Celgene, Millennium, Onyx, Novartis, SmithKline, Prothena, Ionis, and Amgen. S.K.K. received consultancy from Celgene, Millennium, Onyx, Janssen, and BMS, and research funding from Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS. M.Q.L. received research funding from Celgene. D.D. received research funding from Karyopharm Therapeutics, Amgen, and Millennium Pharmaceuticals. P.K. received research funding from Takeda, Celgene, and Amgen. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"52"}}